TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...

WASHINGTON, May 2, 2024 /PRNewswire/ -- The National Association of Investment Companies (NAIC) is pleased to announce the 2024 cohort of Paradigm Changers interns. Launched in 2021, NAIC's Paradigm ...

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...

Paradigm and Film2Future have inked a two-year collaborative agreement that will see the talent agency become the exclusive partner of the non-profit that promotes pathways into the entertainment ...

Nursing instructor Mary Iverson liked to speak Spanish, to socialize, sew. Yet in her late 50s, Mary, wife of cardio-thoracic surgeon Leigh Iverson, and mother to their three daughters, noticed ...

WAYNE, Pa., April 13, 2021 /PRNewswire/ — Evolve IP (R), a leading international service provider of Work AnywhereTM solutions, today announced that Paradigm Technology Group, an IT services ...

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...

This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023, ...

“Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone,” said ...